[14C]ABT-199 (GDC-0199)
Phase 1Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Non-Hodgkin's Lymphoma
Conditions
Relapsed/Refractory Non-Hodgkin's Lymphoma
Trial Timeline
Sep 1, 2014 → Jan 1, 2015
NCT ID
NCT02095574About [14C]ABT-199 (GDC-0199)
[14C]ABT-199 (GDC-0199) is a phase 1 stage product being developed by AbbVie for Relapsed/Refractory Non-Hodgkin's Lymphoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02095574. Target conditions include Relapsed/Refractory Non-Hodgkin's Lymphoma.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory Non-Hodgkin's Lymphoma were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02095574 | Phase 1 | Withdrawn |
Competing Products
20 competing products in Relapsed/Refractory Non-Hodgkin's Lymphoma